SAN DIEGO, May 24, 2017 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) announced today the completion of
its previously announced underwritten public offering of 11,500,000
shares of its common stock. The offering included 1,500,000 shares
sold pursuant to the full exercise of the underwriters' option to
purchase additional shares. All shares in the offering were sold by
Halozyme at a public offering price of $12.50 per share. Net proceeds from the offering,
after deducting underwriting discounts and commissions and
estimated offering expenses, were approximately $135 million.
Halozyme intends to use the net proceeds from this offering to
fund continued development of its PEGPH20 oncology program and for
other general corporate purposes.
Wells Fargo Securities, LLC and Deutsche Bank Securities acted
as joint book-running managers for the offering. Barclays and JMP
Securities acted as co-managers for the offering.
An automatic shelf registration statement on Form S-3 relating
to the public offering of the shares of common stock described
above was filed with the Securities and Exchange Commission (the
"SEC") and is effective. A final prospectus supplement and
accompanying prospectus relating to this offering have been filed
with the SEC. Copies of the final prospectus supplement and
accompanying prospectus may be obtained from Wells Fargo
Securities, LLC, Attention: Equity Syndicate Department, 375 Park
Avenue, New York, New York 10152,
or by telephone at (800) 326-5897 or email to
cmclientsupport@wellsfargo.com; or Deutsche Bank Securities Inc.,
Attention: Prospectus Group, 60 Wall Street, New York, NY 10005, or by telephone at (800)
503-4611 or email to prospectus.cpdg@db.com. Electronic copies of
the final prospectus supplement and accompanying prospectus are
also available on the website of the SEC at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor
microenvironment.
Safe Harbor Statement
All of the statements in this
press release that are not statements of historical facts
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Examples of such
statements include Halozyme's intended use of proceeds. These
statements are based upon management's current plans and
expectations and are subject to a number of risks and uncertainties
which could cause actual results to differ materially from such
statements. A discussion of the risks and uncertainties that can
affect these statements is set forth in Halozyme's prospectus
supplement and the accompanying prospectus filed with the SEC on
May 19, 2017, together with the
information incorporated by reference, under the heading "Risk
Factors." Halozyme disclaims any intention or obligation to
revise or update any forward-looking statements, whether as a
result of new information, future events, or otherwise.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-announces-completion-of-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300463472.html
SOURCE Halozyme Therapeutics, Inc.